 |
| |
| Oct-29-14 | Reiterated |
Argus |
Buy |
$140 → $185 |
|
| Oct-28-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$150 → $165 |
|
| Sep-08-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$138 → $150 |
|
| Aug-04-14 | Reiterated |
Argus |
Buy |
$135 → $140 |
|
| Jul-30-14 | Reiterated |
RBC Capital Mkts |
Outperform |
$125 → $138 |
|
| Jul-18-14 | Reiterated |
Deutsche Bank |
Buy |
$144 → $149 |
|
| Apr-23-14 | Reiterated |
Oppenheimer |
Perform |
$121 → $122 |
|
| Mar-21-14 | Reiterated |
Barclays |
Equal Weight |
$115 → $130 |
|
| Jan-31-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| Nov-20-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| Aug-29-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| Aug-27-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| Jul-31-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| Apr-24-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| Apr-15-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| Apr-08-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| Jan-25-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| Jan-24-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| Sep-12-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| Sep-10-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
|
|
| Mar-02-15 12:31AM | Amgen Sees Positive Results From Kyprolis Study at The Wall Street Journal |
| Mar-01-15 11:15PM | Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results at The Wall Street Journal |
| 10:25PM | Amgen Multiple Myeloma Drug Kyprolis Tops Rival in Study at TheStreet |
| 09:13PM | Amgen Sees Positive Results From Kyprolis Study at The Wall Street Journal |
| 08:22PM | Amgen's Kyprolis Outperforms Rival Drug In Study at Forbes |
| 08:12PM | Amgen says a study found its cancer drug more effective than rival drug at Los Angeles Times |
| 07:01PM | Amgen says Kyprolis doubles progression-free survival vs Velcade Reuters |
| 07:00PM | Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma PR Newswire |
| Feb-28-15 07:36PM | Amgen's Kyprolis Under EU Review - Analyst Blog Zacks |
| 12:35PM | Stock Market Video Analysis for Week Ending 2/27/15 Yahoo Finance Contributors |
| Feb-27-15 06:02PM | Final Glance: Biotechnology companies AP |
| 05:30PM | Bellevue city manager: Keeping Expedia in Bellevue a 'top priority' at bizjournals.com |
| 03:45PM | Expedia may move to Amgen's former Seattle campus at bizjournals.com |
| 01:26PM | Midday Glance: Biotechnology companies AP |
| 11:10AM | Early Glance: Biotechnology companies AP |
| 09:30AM | The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Zacks |
| 09:00AM | Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer PR Newswire |
| Feb-26-15 04:05PM | Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma PR Newswire |
| 01:25PM | Short Sellers Come Back To Biotech Stocks Benzinga |
| 01:04PM | AMGEN INC Financials EDGAR Online Financials |
| 11:20AM | Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks |
| 11:07AM | Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks |
| 09:45AM | Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers at American City Business Journals |
| 09:25AM | Short Sellers Increase Bets Against Biotech as Shares Continue to Rise at 24/7 Wall St. |
| Feb-25-15 06:04PM | Amgen Drug Shows Positive Results in Late-Phase Study at The Wall Street Journal |
| 04:44PM | Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis PR Newswire |
| 04:04PM | Amgen To Present At The Cowen And Company 35th Annual Health Care Conference PR Newswire |
| Feb-23-15 07:58PM | Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires 5 Hottest Biotech Picks at Insider Monkey |
| 07:44PM | [video]Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble at TheStreet |
| 11:06AM | Big pharma invests big money in research and development Market Realist |
| 10:05AM | Third Point ups its stake in Amgen Market Realist |
| Feb-21-15 07:08PM | 10-K for Amgen, Inc. Company Spotlight |
| 03:04PM | Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capitals Top Stock Picks and New Moves at Insider Monkey |
| Feb-19-15 05:06PM | AMGEN INC Files SEC form 10-K, Annual Report EDGAR Online |
| 10:40AM | Actavis (ACT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet |
| Feb-18-15 06:04PM | A Look At Dan Loeb's Diversified 13F Benzinga |
| Feb-17-15 05:55PM | CVS urges cost controls for new cholesterol drugs Reuters |
| 04:59PM | CVS girds for battle over cholesterol drugs at MarketWatch |
| 09:29AM | Daniel Loeb's Third Point Boosted Stakes of Amgen, Alibaba in 4Q at Barrons.com |
| Feb-16-15 08:36AM | If Pfizer's Right, Hospira Biosimilar Gold Rush Begins at Forbes |
| Feb-12-15 04:10PM | Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog Zacks |
| 08:44AM | Brookdale scales up in response to industry dynamics Market Realist |
| Feb-11-15 04:22PM | Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma PR Newswire |
| 10:40AM | Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog Zacks |
| Feb-10-15 04:38PM | Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily |
| 11:01AM | Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily |
| 04:22AM | Career Booster for CFOs: a Stint Abroad at The Wall Street Journal |
| Feb-06-15 12:31PM | Fat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever at Fortune |
| 10:10AM | Stock Market News for February 06, 2015 - Market News Zacks |
| 07:18AM | How Obamacare Made Hospira A Lucrative Target For Pfizer at Forbes |
| Feb-05-15 06:20PM | bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog Zacks |
| 05:33PM | Generic-Drug Makers Soar, And It's Easy To See Why at Investor's Business Daily |
| 09:30AM | The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks |
| Feb-04-15 04:25PM | Amgen Reveals Positive Results on Biosimilar Candidate - Analyst Blog Zacks |
| 03:55PM | In speed mode, FDA approves Pfizers big new drug early at Fortune |
| 12:36PM | Safe biotech plays CNBC |
| 11:47AM | Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog Zacks |
| 11:21AM | Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog Zacks |
| 10:45AM | Gilead Dividend and Buyback Different From Amgens Strategy at 24/7 Wall St. |
| 10:22AM | Will Dividend Investors Find Gilead? at Barrons.com |
| Feb-03-15 06:14PM | [$$] Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results at The Wall Street Journal |
| 04:57PM | Amgen: Its biosimilar version of Humira about as effective AP |
| 04:49PM | Paying Dividends: Gilead Initiates First Quarterly Payout at Barrons.com |
| 04:01PM | Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis PR Newswire |
| Jan-29-15 04:40PM | Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia PR Newswire |
| Jan-28-15 04:46PM | Wednesday's Market Recap Yahoo Finance Contributors |
| 03:37PM | Correction: Earns-Amgen story AP |
| 12:53PM | Wait, I Thought Amgen Reported Solid Earnings? at Barrons.com |
| 12:30PM | Amgen (AMGN) Stock Declines Today Despite Earnings Beat at TheStreet |
| 10:00AM | Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog Zacks |
| 07:49AM | Amgen (AMGN) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet |
| Jan-27-15 07:10PM | Amgen Profit Rises 27% on Higher Sales of Key Drugs at The Wall Street Journal |
| 06:40PM | Amgen tops Street 4Q forecasts AP |
| 05:45PM | Amgen fourth-quarter earnings, revenue beat estimates at Los Angeles Times |
| 05:20PM | Amgen Beats Q4 Expectations Benzinga |
| 05:12PM | Amgen profit tops expectations on Enbrel sales, tax credit Reuters |
| 05:12PM | Stocks Weaken Late; Apple Jumps After Hours at Investor's Business Daily |
| 05:01PM | Updates, advisories and surprises at MarketWatch |
| 05:00PM | Amgen Inc Earnings Call scheduled for 5:00 pm ET today CCBN |
| 05:00PM | After-hours buzz: AT&T, Apple, Yahoo & more at CNBC |
| 04:45PM | Amgen (AMGN) Stock Rises in After-Hours Trading Today on Fourth-Quarter Earnings Beat at TheStreet |
| 04:28PM | Amgen profit beats forecasts at MarketWatch |
| 04:17PM | Amgen Climbs On Q4 Beat at Barrons.com |
| 04:16PM | AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:02PM | Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma PR Newswire |
| 04:01PM | Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 PR Newswire |
| 12:31PM | What to Expect When Amgen (AMGN) Reports Fourth-Quarter Earnings After Market Close Today at TheStreet |
| 10:19AM | Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog Zacks |
| 07:07AM | Q4 2014 Amgen Inc Earnings Release - After Market Close CCBN |
| Jan-26-15 12:00PM | TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog Zacks |
| 08:02AM | Can CAR-T Therapy Live Up To The Biotech IPO Hype? at Investor's Business Daily |
| 06:53AM | Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune |
| 02:46AM | Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes |
| Jan-23-15 06:25PM | Will Amgen (AMGN) Keep the Earnings Streak Alive in 4Q? - Analyst Blog Zacks |
| 04:20PM | Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Zacks |
| 06:15AM | Up to Speed: Death of Saudi king moves needle on oil prices (Video) at American City Business Journals |
| Jan-22-15 07:00PM | UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Zacks |
| 06:35PM | Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Zacks |
| 06:00PM | BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks |
| 05:40PM | Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog Zacks |
|
|
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BALTIMORE DAVID | Director | Feb 19 | Option Exercise | 42.13 | 5,000 | 210,650 | 36,159 | Feb 23 04:13 PM | | Bradway Robert A | Chairman, CEO and President | Feb 11 | Option Exercise | 42.13 | 84,000 | 3,538,920 | 258,641 | Feb 12 09:09 PM | | Bradway Robert A | Chairman, CEO and President | Feb 11 | Sale | 152.69 | 22,000 | 3,359,116 | 218,102 | Feb 12 09:09 PM | | COFFMAN VANCE D | Director | Feb 06 | Option Exercise | 42.13 | 5,000 | 210,650 | 38,460 | Feb 06 06:23 PM | | HERRINGER FRANK C | Director | Feb 05 | Option Exercise | 42.13 | 5,000 | 210,650 | 25,449 | Feb 05 08:11 PM | | HERRINGER FRANK C | Director | Feb 05 | Buy | 152.29 | 3,000 | 456,870 | 2,000 | Feb 05 08:11 PM | | de Carbonnel Francois | Director | Dec 03 | Sale | 168.01 | 3,000 | 504,041 | 19,159 | Dec 03 05:00 PM | | COFFMAN VANCE D | Director | Sep 05 | Option Exercise | 56.79 | 20,000 | 1,135,800 | 41,623 | Sep 09 06:54 PM | | Harper Sean E | EVP, Research & Development | Aug 05 | Sale | 127.29 | 14,000 | 1,782,126 | 59,503 | Aug 07 04:22 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Option Exercise | 56.64 | 4,130 | 233,911 | 22,719 | May 22 05:15 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 21 | Sale | 112.83 | 4,130 | 465,984 | 18,589 | May 22 05:15 PM | | Bradway Robert A | Chairman, CEO and President | May 12 | Buy | 111.77 | 894 | 99,919 | 185,013 | May 12 08:33 PM | | Michael A Kelly | Acting CFO | Apr 28 | Sale | 110.45 | 2,065 | 228,072 | 41,041 | Apr 29 05:48 PM | | de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM |
|
|
|
|
|
|
